Synbiotics easing renal failure by improving Gut microbiology (SYNERGY): A protocol of placebo-controlled randomised cross-over trial

Megan Rossi, David W Johnson, Mark Morrison, Elaine Pascoe, Jeff S Coombes, Josephine M Forbes, Brett C McWhinney, Jacobus P J Ungerer, Goce Dimeski, Katrina L Campbell

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

BACKGROUND: Emerging evidence suggests modulating the microbiota in the large bowel of patients with chronic kidney disease (CKD) through pre- and/probiotic supplementation may inhibit the development of key nephrovascular toxins. To date, quality intervention trials investigating this novel treatment in CKD are lacking. The aim of SYNERGY is to assess the effectiveness of synbiotics (co-administration of pre- and probiotics) as a potential treatment targeting the synthesis of uremic toxins, specifically, indoxyl sulphate (IS) and p-cresyl sulphate (PCS).

METHODS/DESIGN: Thirty-seven patients with moderate to severe CKD (Stage IV and V, pre-dialysis) will be recruited to a double-blind, placebo-controlled, randomised cross-over trial. Patients will be provided with synbiotic therapy or placebo for 6 weeks, with a 4 week washout before cross-over. The primary outcome is serum IS, total and free (unbound) concentrations, measured using ultra-performance liquid chromatography. Secondary outcomes include serum PCS, total and free (unbound) concentrations; cardiovascular risk, measured by serum lipopolysaccharides, serum trimethylamine-N-oxide (TMAO) and inflammation and oxidative stress markers; kidney damage, measured by 24 hour proteinuria and albuminuria, estimated glomerular filtration rate and renal tubule damage (urinary kidney injury molecule-1); patients' self assessed quality of life; and gastrointestinal symptoms. In addition, the effects on the community structure of the stool microbiota will be explored in a subset of patients to validate the mechanistic rationale underpinning the synbiotic therapy.

DISCUSSION: IS and PCS are two novel uremic toxins implicated in both cardiovascular disease (CVD) and progression of CKD. Preliminary studies indicate that synbiotic therapy maybe a promising strategy when considering a targeted, tolerable and cost-efficient therapy for lowering serum IS and PCS concentrations. This trial will provide high quality 'proof-of-concept' data to elucidate both the efficacy of synbiotic therapy for lowering the toxins and whether reductions in serum IS and PCS translate into clinical benefits. Considering the potential of pre- and probiotics to not only shift toxin levels, but to also impede CVD and CKD progression, SYNERGY will provide vital insight into the effectiveness of this innocuous nutritional therapy.

TRIAL REGISTRATION: Universal Trial Number: U1111-1142-4363. Australian New Zealand Clinical Trials Registry Number: ACTRN12613000493741, date registered: 2nd May 2013.

Original languageEnglish
Pages (from-to)106
JournalBMC Nephrology
Volume15
DOIs
Publication statusPublished - 4 Jul 2014
Externally publishedYes

Fingerprint

Synbiotics
Microbiology
Indican
Cross-Over Studies
Renal Insufficiency
Placebos
Chronic Renal Insufficiency
Sulfates
Probiotics
Serum
Microbiota
Therapeutics
Kidney
Disease Progression
Cardiovascular Diseases
Prebiotics
Albuminuria
Glomerular Filtration Rate
New Zealand
Proteinuria

Cite this

Rossi, Megan ; Johnson, David W ; Morrison, Mark ; Pascoe, Elaine ; Coombes, Jeff S ; Forbes, Josephine M ; McWhinney, Brett C ; Ungerer, Jacobus P J ; Dimeski, Goce ; Campbell, Katrina L. / Synbiotics easing renal failure by improving Gut microbiology (SYNERGY): A protocol of placebo-controlled randomised cross-over trial. In: BMC Nephrology. 2014 ; Vol. 15. pp. 106.
@article{4fca73fff72e4d2f9e05a760781dfbc3,
title = "Synbiotics easing renal failure by improving Gut microbiology (SYNERGY): A protocol of placebo-controlled randomised cross-over trial",
abstract = "BACKGROUND: Emerging evidence suggests modulating the microbiota in the large bowel of patients with chronic kidney disease (CKD) through pre- and/probiotic supplementation may inhibit the development of key nephrovascular toxins. To date, quality intervention trials investigating this novel treatment in CKD are lacking. The aim of SYNERGY is to assess the effectiveness of synbiotics (co-administration of pre- and probiotics) as a potential treatment targeting the synthesis of uremic toxins, specifically, indoxyl sulphate (IS) and p-cresyl sulphate (PCS).METHODS/DESIGN: Thirty-seven patients with moderate to severe CKD (Stage IV and V, pre-dialysis) will be recruited to a double-blind, placebo-controlled, randomised cross-over trial. Patients will be provided with synbiotic therapy or placebo for 6 weeks, with a 4 week washout before cross-over. The primary outcome is serum IS, total and free (unbound) concentrations, measured using ultra-performance liquid chromatography. Secondary outcomes include serum PCS, total and free (unbound) concentrations; cardiovascular risk, measured by serum lipopolysaccharides, serum trimethylamine-N-oxide (TMAO) and inflammation and oxidative stress markers; kidney damage, measured by 24 hour proteinuria and albuminuria, estimated glomerular filtration rate and renal tubule damage (urinary kidney injury molecule-1); patients' self assessed quality of life; and gastrointestinal symptoms. In addition, the effects on the community structure of the stool microbiota will be explored in a subset of patients to validate the mechanistic rationale underpinning the synbiotic therapy.DISCUSSION: IS and PCS are two novel uremic toxins implicated in both cardiovascular disease (CVD) and progression of CKD. Preliminary studies indicate that synbiotic therapy maybe a promising strategy when considering a targeted, tolerable and cost-efficient therapy for lowering serum IS and PCS concentrations. This trial will provide high quality 'proof-of-concept' data to elucidate both the efficacy of synbiotic therapy for lowering the toxins and whether reductions in serum IS and PCS translate into clinical benefits. Considering the potential of pre- and probiotics to not only shift toxin levels, but to also impede CVD and CKD progression, SYNERGY will provide vital insight into the effectiveness of this innocuous nutritional therapy.TRIAL REGISTRATION: Universal Trial Number: U1111-1142-4363. Australian New Zealand Clinical Trials Registry Number: ACTRN12613000493741, date registered: 2nd May 2013.",
author = "Megan Rossi and Johnson, {David W} and Mark Morrison and Elaine Pascoe and Coombes, {Jeff S} and Forbes, {Josephine M} and McWhinney, {Brett C} and Ungerer, {Jacobus P J} and Goce Dimeski and Campbell, {Katrina L}",
year = "2014",
month = "7",
day = "4",
doi = "10.1186/1471-2369-15-106",
language = "English",
volume = "15",
pages = "106",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central Ltd.",

}

Rossi, M, Johnson, DW, Morrison, M, Pascoe, E, Coombes, JS, Forbes, JM, McWhinney, BC, Ungerer, JPJ, Dimeski, G & Campbell, KL 2014, 'Synbiotics easing renal failure by improving Gut microbiology (SYNERGY): A protocol of placebo-controlled randomised cross-over trial' BMC Nephrology, vol. 15, pp. 106. https://doi.org/10.1186/1471-2369-15-106

Synbiotics easing renal failure by improving Gut microbiology (SYNERGY): A protocol of placebo-controlled randomised cross-over trial. / Rossi, Megan; Johnson, David W; Morrison, Mark; Pascoe, Elaine; Coombes, Jeff S; Forbes, Josephine M; McWhinney, Brett C; Ungerer, Jacobus P J; Dimeski, Goce; Campbell, Katrina L.

In: BMC Nephrology, Vol. 15, 04.07.2014, p. 106.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Synbiotics easing renal failure by improving Gut microbiology (SYNERGY): A protocol of placebo-controlled randomised cross-over trial

AU - Rossi, Megan

AU - Johnson, David W

AU - Morrison, Mark

AU - Pascoe, Elaine

AU - Coombes, Jeff S

AU - Forbes, Josephine M

AU - McWhinney, Brett C

AU - Ungerer, Jacobus P J

AU - Dimeski, Goce

AU - Campbell, Katrina L

PY - 2014/7/4

Y1 - 2014/7/4

N2 - BACKGROUND: Emerging evidence suggests modulating the microbiota in the large bowel of patients with chronic kidney disease (CKD) through pre- and/probiotic supplementation may inhibit the development of key nephrovascular toxins. To date, quality intervention trials investigating this novel treatment in CKD are lacking. The aim of SYNERGY is to assess the effectiveness of synbiotics (co-administration of pre- and probiotics) as a potential treatment targeting the synthesis of uremic toxins, specifically, indoxyl sulphate (IS) and p-cresyl sulphate (PCS).METHODS/DESIGN: Thirty-seven patients with moderate to severe CKD (Stage IV and V, pre-dialysis) will be recruited to a double-blind, placebo-controlled, randomised cross-over trial. Patients will be provided with synbiotic therapy or placebo for 6 weeks, with a 4 week washout before cross-over. The primary outcome is serum IS, total and free (unbound) concentrations, measured using ultra-performance liquid chromatography. Secondary outcomes include serum PCS, total and free (unbound) concentrations; cardiovascular risk, measured by serum lipopolysaccharides, serum trimethylamine-N-oxide (TMAO) and inflammation and oxidative stress markers; kidney damage, measured by 24 hour proteinuria and albuminuria, estimated glomerular filtration rate and renal tubule damage (urinary kidney injury molecule-1); patients' self assessed quality of life; and gastrointestinal symptoms. In addition, the effects on the community structure of the stool microbiota will be explored in a subset of patients to validate the mechanistic rationale underpinning the synbiotic therapy.DISCUSSION: IS and PCS are two novel uremic toxins implicated in both cardiovascular disease (CVD) and progression of CKD. Preliminary studies indicate that synbiotic therapy maybe a promising strategy when considering a targeted, tolerable and cost-efficient therapy for lowering serum IS and PCS concentrations. This trial will provide high quality 'proof-of-concept' data to elucidate both the efficacy of synbiotic therapy for lowering the toxins and whether reductions in serum IS and PCS translate into clinical benefits. Considering the potential of pre- and probiotics to not only shift toxin levels, but to also impede CVD and CKD progression, SYNERGY will provide vital insight into the effectiveness of this innocuous nutritional therapy.TRIAL REGISTRATION: Universal Trial Number: U1111-1142-4363. Australian New Zealand Clinical Trials Registry Number: ACTRN12613000493741, date registered: 2nd May 2013.

AB - BACKGROUND: Emerging evidence suggests modulating the microbiota in the large bowel of patients with chronic kidney disease (CKD) through pre- and/probiotic supplementation may inhibit the development of key nephrovascular toxins. To date, quality intervention trials investigating this novel treatment in CKD are lacking. The aim of SYNERGY is to assess the effectiveness of synbiotics (co-administration of pre- and probiotics) as a potential treatment targeting the synthesis of uremic toxins, specifically, indoxyl sulphate (IS) and p-cresyl sulphate (PCS).METHODS/DESIGN: Thirty-seven patients with moderate to severe CKD (Stage IV and V, pre-dialysis) will be recruited to a double-blind, placebo-controlled, randomised cross-over trial. Patients will be provided with synbiotic therapy or placebo for 6 weeks, with a 4 week washout before cross-over. The primary outcome is serum IS, total and free (unbound) concentrations, measured using ultra-performance liquid chromatography. Secondary outcomes include serum PCS, total and free (unbound) concentrations; cardiovascular risk, measured by serum lipopolysaccharides, serum trimethylamine-N-oxide (TMAO) and inflammation and oxidative stress markers; kidney damage, measured by 24 hour proteinuria and albuminuria, estimated glomerular filtration rate and renal tubule damage (urinary kidney injury molecule-1); patients' self assessed quality of life; and gastrointestinal symptoms. In addition, the effects on the community structure of the stool microbiota will be explored in a subset of patients to validate the mechanistic rationale underpinning the synbiotic therapy.DISCUSSION: IS and PCS are two novel uremic toxins implicated in both cardiovascular disease (CVD) and progression of CKD. Preliminary studies indicate that synbiotic therapy maybe a promising strategy when considering a targeted, tolerable and cost-efficient therapy for lowering serum IS and PCS concentrations. This trial will provide high quality 'proof-of-concept' data to elucidate both the efficacy of synbiotic therapy for lowering the toxins and whether reductions in serum IS and PCS translate into clinical benefits. Considering the potential of pre- and probiotics to not only shift toxin levels, but to also impede CVD and CKD progression, SYNERGY will provide vital insight into the effectiveness of this innocuous nutritional therapy.TRIAL REGISTRATION: Universal Trial Number: U1111-1142-4363. Australian New Zealand Clinical Trials Registry Number: ACTRN12613000493741, date registered: 2nd May 2013.

U2 - 10.1186/1471-2369-15-106

DO - 10.1186/1471-2369-15-106

M3 - Article

VL - 15

SP - 106

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

ER -